|
Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study. |
|
|
Honoraria - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Merck; Roche |
Consulting or Advisory Role - Bayer Schering Pharma |
|
|
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb; BTG; Eisai; Ipsen; MSD; Roche |
Research Funding - Beigene (Inst); Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche |
|
|
Honoraria - Bayer Schering Pharma |
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Roche; Sirtex Medical |
Speakers' Bureau - Bayer; Roche; SIRTEX Medical |
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Ipsen; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; MSD Oncology; Novartis |
|
|
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology |
Consulting or Advisory Role - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Honoraria - Novartis; Roche Canada |
Consulting or Advisory Role - AstraZeneca/MedImmune; Lilly; Merck |
Research Funding - AstraZeneca; Ipsen; Merck |
Expert Testimony - AstraZeneca |
|
|
Honoraria - AstraZeneca; Bayer; Eisai; Ipsen; Lilly; MSD; Roche |
Consulting or Advisory Role - Eisai; Ipsen; MSD; Roche; Sanofi |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Gilead Sciences; Gilead Sciences; Lilly; Merck; Roche/Genentech; Sanofi/Aventis |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst) |
|
Valeriy Vladimirovich Breder |
Honoraria - Bayer; BioCad; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche; Takeda |
Consulting or Advisory Role - Bayer; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche |
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Ipsen; Roche; Takeda |
|
|
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology |
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai |
|
|
|
Honoraria - Bayer; Eisai; Lilly; Merck |
Consulting or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; Eisai; Lilly; Merck |
Research Funding - Bayer; Eisai; Lilly |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
|